Orano Med, a French-based biotechnology company, celebrated the completion of a new Alpha Therapy Laboratory (ATLab) in Brownsburg, Indiana, in June 2024. It is the first industrial-scale pharmaceutical manufacturing facility in the United States to manufacture this treatment. This pioneering facility marks a significant milestone in the development and distribution of leading-edge therapeutics, particularly those involving isotopes like lead-212 radioligand therapies known as targeted alpha therapies (TAT), which are known for their application in targeted cancer treatments.
Lead-212, despite its short half-life of only 10.6 hours, has emerged as a beacon of hope in the fight against complex cancer cases. However, this characteristic poses a unique challenge - it necessitates the production of therapies close to healthcare facilities to ensure they are administered while at their most potent. The ATLab in Brownsburg is a direct response to this challenge, designed to bolster the rapid development and deployment of life-saving treatments to patients in need, not just domestically but around the globe.
Establishing the first US ATLab in Brownsburg reflects a strategic move, recognizing the town's growing stature as a key player in the healthcare and biotechnology sectors. Positioned within reach of significant hospital networks, the Brownsburg facility is expected to play a crucial role in meeting the global demand for advanced medical therapies. In addition, ATLab Indianapolis will benefit from the interstate network of the Indianapolis metropolitan area. Its proximity to the Indianapolis International Airport is one of the key factors in selecting the location.
ATLab Indianapolis, with over 30,000 sq. ft. of floor space, will represent an investment of $20 million and create approximately 25 direct jobs. Production lines have been designed using a modular approach, enabling the addition of more lines in the future. This flexibility will allow for the manufacture and distribution of multiple drugs simultaneously, potentially increasing efficiency and scalability in pharmaceutical production. The facility will initially produce 5,000 patient doses a year to serve the US market, with plans to expand the output tenfold by the end of the decade.